VALUE-Dx

VALUE-Dx is the first Innovative Medicines Initiative project initiated by 6 in vitro diagnostic companies who joined forces with 20 non-industry partners to combat antimicrobial resistance and improve patient outcomes. Unique in its multidisciplinary consortium, it involves clinicians, microbiologists, health economists, social scientists, and industry, to help build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance. VALUE-Dx will focus its research on community care, which is defined as the first point of contact with health services. Innovative diagnostics could transform clinical care, especially in community care settings where the majority of antibiotics are prescribed, by reducing uncertainty about potential benefit antibiotics may offer to individuals. VALUE-Dx will focus on diagnostic strategies relevant to reducing AMR in Community-Acquired Acute Respiratory Tract Infections.